Rare diseases
Investigational molecules
Locations
Chloroquine phosphate is a medication that has been used for over 70 years in various medical applications. It belongs to the class of drugs known as 4-aminoquinolines, which are synthetic derivatives of quinine, a compound originally extracted from the bark of the Cinchona tree [1]. Chloroquine is available in tablet form, with each tablet typically containing 250 mg of chloroquine phosphate (equivalent to 150 mg of chloroquine base).
Common brand names for chloroquine phosphate include Aralen, Chloroquine, and Plasmodín. In some regions, the drug may also be known as Chloroquine diphosphate or A-CQ [2].
Chloroquine phosphate has several established medical uses, with the most significant applications including:
Chloroquine has been widely used since 1946 for both treatment and prevention (prophylaxis) of malaria [3]. It is particularly effective against certain types of the malaria parasite, including:
For uncomplicated malaria, chloroquine is typically administered as a 3-day regimen with a total dose of 25 mg/kg body weight [4]. However, due to increasing resistance of Plasmodium falciparum to chloroquine in many parts of the world, its use has been limited in regions where resistant strains are common.
Chloroquine has anti-inflammatory properties that make it useful in treating certain autoimmune conditions [5], including:
In these conditions, chloroquine helps reduce inflammation and modify the immune system's response. For autoimmune hepatitis, studies have shown that chloroquine can help maintain remission after withdrawal of standard treatments [6].
Research has explored additional applications for chloroquine, including:
Chloroquine's mechanisms of action vary depending on the condition being treated:
As an antimalarial agent, chloroquine:
In autoimmune conditions, chloroquine:
Some research suggests chloroquine may have antiviral properties by:
Chloroquine dosage varies significantly based on the condition being treated, the patient's weight, and other factors. Always follow your healthcare provider's specific instructions.
The standard adult dosage for treating uncomplicated malaria is typically:
For children or adults under 60 kg, the dosage is adjusted based on weight.
For prophylaxis (prevention) in areas with chloroquine-sensitive malaria:
For conditions like autoimmune hepatitis:
While chloroquine is generally considered safe when used as directed, it can cause various side effects ranging from mild to severe.
Mild and transient side effects may include:
More severe reactions that require immediate medical attention include:
One of the most concerning adverse effects of chloroquine is retinal damage, which can occur with long-term use. This risk increases with:
To minimize this risk, regular ophthalmologic examinations (every 4-6 months) are recommended for patients on long-term chloroquine therapy.
Chloroquine can prolong the QT interval on electrocardiogram (ECG), potentially leading to serious cardiac arrhythmias. This risk is higher in patients with:
Chloroquine can interact with various medications, potentially increasing the risk of side effects or reducing effectiveness.
Chloroquine is considered relatively safe during pregnancy, particularly for malaria treatment and prevention. It has been widely used for decades in pregnant women with no evidence of significant harm to the fetus [18]. Chloroquine is also considered safe during breastfeeding, as the amount excreted in breast milk is not sufficient to harm the infant.
Unlike primaquine, chloroquine is generally considered safe for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In fact, chloroquine is often used as an alternative treatment in these patients when primaquine is contraindicated [19].
Chloroquine can be used in children, with dosage adjusted based on weight. However, children may be more sensitive to chloroquine toxicity, so careful dosing is essential [20].
Older adults may be more sensitive to the effects of chloroquine and may require dosage adjustments. They are also at higher risk for side effects, particularly retinal toxicity and cardiac effects [21].
During the COVID-19 pandemic, chloroquine was investigated as a potential treatment for SARS-CoV-2 infection. Early laboratory studies suggested that chloroquine might inhibit virus entry into cells and reduce viral replication [22].
Several clinical trials were conducted to evaluate the efficacy and safety of chloroquine in COVID-19 patients, including:
However, subsequent larger clinical trials did not demonstrate significant benefits for COVID-19 treatment, and concerns about potential cardiac toxicity led most medical authorities to recommend against its use for this indication outside of clinical trials [26].
Research continues to explore new potential applications for chloroquine:
Studies are investigating chloroquine's potential as an adjunct to cancer therapy. It may enhance the effectiveness of certain chemotherapy drugs by inhibiting autophagy (a cellular process that cancer cells can use to survive treatment) [27].
Early research is examining whether chloroquine could help terminate persistent atrial fibrillation, potentially offering a new pharmacological approach to managing this common heart rhythm disorder [28].
Some studies have explored chloroquine's ability to modulate T-cell immune activation in HIV-infected individuals. It may help improve CD4 T-cell recovery in patients receiving antiretroviral therapy [29].
Research has evaluated chloroquine's potential for preventing influenza infection, though results have been mixed [30].
As with any medication, it's important to use chloroquine only as prescribed by your healthcare provider. Regular monitoring is essential, particularly for patients on long-term therapy, to detect and manage potential side effects early.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
